Appropriateness of ordering serum angiotensin-converting enzyme during renin-angiotensin-aldosterone system inhibitor therapy

A Betrains; P Vermeersch; S Vanderschueren

doi:10.1016/j.ejim.2018.09.018

Appropriateness of ordering serum angiotensin-converting enzyme during renin-angiotensin-aldosterone system inhibitor therapy

Eur J Intern Med. 2019 Jan:59:e18-e19. doi: 10.1016/j.ejim.2018.09.018. Epub 2018 Oct 5.

Authors

A Betrains¹, P Vermeersch², S Vanderschueren³

Affiliations

¹ Clinical Department of Internal Medicine, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
² Clinical Department of Laboratory Medicine, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
³ Clinical Department of General Internal Medicine, University Hospitals Leuven Research Department of Microbiology and Immunology, Laboratory for Clinical Infectious and Inflammatory Disorders, KU Leuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address: steven.vanderschueren@uzleuven.be.

PMID: 30297248
DOI: 10.1016/j.ejim.2018.09.018

No abstract available

Keywords: Angiotensin II receptor blockers; Angiotensin converting enzyme; Angiotensin-converting enzyme inhibitors; Kininase II; Renin-angiotensin-aldosterone system; Sarcoidosis.

Publication types

Letter

MeSH terms

Angiotensin Receptor Antagonists / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Biomarkers
Humans
Peptidyl-Dipeptidase A / blood*
Retrospective Studies
Sarcoidosis / drug therapy*
Sarcoidosis / enzymology

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Biomarkers
Peptidyl-Dipeptidase A